Thus, despite the short half-life of [18F]AlF-NOTA-iPD-L1, it can be useful for initially determining tumor PD-L1 expression, and thereby the feasibility of administering [177Lu]Lu-DOTA-iPD-L1 as a combined modality of targeted radiotherapy and anti-PD-L1 immunotherapy. The gene discussed is CD274; the disease is neoplasm.